IAS 2015 Towards an HIV Cure symposium Vancouver. Distinct HIV Genetic Populations in Effector Memory T Cells after Prolonged Therapy

Similar documents
Identification and Characterization of CD4 T cells actively transcribing HIV RNA in Peripheral Blood

T Memory Stem Cells: A Long-term Reservoir for HIV-1

With over 20 drugs and several viable regimens, the mo6vated pa6ent with life- long access to therapy can control HIV indefinitely, elimina6ng the

Alexander O. Pasternak, Mirte Scherpenisse, Ben Berkhout

Towards an HIV Cure. Steven G. Deeks Professor of Medicine University of California, San Francisco

Supplementary Figure 1. Gating strategy and quantification of integrated HIV DNA in sorted CD4 + T-cell subsets.

Biology of Immune Aging

The HIV Cure Agenda. CHIVA Oct Nigel Klein. Institute of Child Health and Great Ormond Street Hospital, London, UK

HIV Antibody Characterization for Reservoir and Eradication Studies. Michael Busch, Sheila Keating, Chris Pilcher, Steve Deeks

Fayth K. Yoshimura, Ph.D. September 7, of 7 HIV - BASIC PROPERTIES

IAS 2015 Towards an HIV Cure symposium Vancouver Immune recognition following latency reversal

Approaching a Cure Daniel R. Kuritzkes, MD

HIV 101: Fundamentals of HIV Infection

HIV Immunopathogenesis. Modeling the Immune System May 2, 2007

Complete Transcriptome Analysis of Latently Infected CD4 + T Cells

Effector mechanisms of cell-mediated immunity: Properties of effector, memory and regulatory T cells

MHRP. Outline. Is HIV cure possible? HIV persistence. Cure Strategies. Ethical and social considerations. Short video on patients perspectives on cure

How HIV Causes Disease Prof. Bruce D. Walker

CHARACTERIZATION OF HIV-1 POPULATIONS IN INFECTED CELLS

persistence during therapy Professor of Medicine University of California, San Francisco

Impact of Vorinostat Treatment of Non- Hodgkin s Lymphoma on HIV-1 Latent Reservoir

HIV Reservoirs in Developing Countries: Implication for HIV CURE Strategies

Combination antiretroviral therapy (ART) has. Differentiating Immune Cell Targets in Gut-Associated Lymphoid Tissue for HIV Cure

SYSTEMS BIOLOGY APPROACHES TO IDENTIFY MECHANISMS OF IMMUNE MEDIATED PROTECTION TRANSLATING RESEARCH INTO HEALTH

Structure of HIV. Virion contains a membrane envelope with a single viral protein= Env protein. Capsid made up of Gag protein

Additional Presentation Demonstrates Potential Mechanisms for Unprecedented HIV Reservoir Depletion by SB-728-T

HIV-1 DNA levels after antiretroviral therapy in primary infection predict disease progression: the SPARTAC Trial

HIV disease progression is associated with exhaustion of lymphopoiesis driven by immune activation

HIV-DNA: nuovo marcatore virologico. Metodiche a confronto per la quantificazione di HIV-DNA

Can HIV be cured? (how about long term Drug free remission?)

Cellular Immunity in Aging and HIV: Correlates of Protection. Immune Senescence

Professor Jonathan Weber

HIV cure: current status and implications for the future

Establishment and Targeting of the Viral Reservoir in Rhesus Monkeys

Innovative diagnostics for HIV, HBV and HCV

Inconsistent HIV reservoir dynamics and immune responses following anti-pd-1 therapy

Potential cross reactions between HIV 1 specific T cells and the microbiome. Andrew McMichael Suzanne Campion

Human Immunodeficiency Virus

2015 TOWARDS AN HIV CURE SYMPOSIUM. Abstract Book 18 & 19 July 2015 Vancouver, Canada

Invited Review CROI 2018: Advances in Basic Science Understanding of HIV

What s New in Acute HIV Infection?

I declare that I have no financial conflicts of interest

7.012 Quiz 3 Answers

Induction and Clearance of Latent HIV Infection:

MID-TERM EXAMINATION

Immunization with single-cycle SIV significantly reduces viral loads after an intravenous challenge with SIV(mac)239

Immunization with Single-Cycle SIV Significantly Reduces Viral Loads After an Intravenous Challenge with SIV mac 239

Journal of Infectious Diseases Advance Access published July 11, Effect of Antiretroviral Therapy on HIV Reservoirs in Elite Controllers

B and T cell Memory. Bengt Lindbom Adap6ve Immunity BMC D14

AIDS free generation. Bob Colebunders Institute of Tropical Medicine

Sangamo BioSciences Presents Phase 2 Clinical Data From Two SB-728-T HIV Studies

Alternate Antibody-Based Therapeutic Strategies To Purge the HIV Cell Reservoir

Case Study. Dr Sarah Sasson Immunopathology Registrar. HIV, Immunology and Infectious Diseases Department and SydPath, St Vincent's Hospital.

Viral Reservoirs and anti-latency interventions in nonhuman primate models of SIV/SHIV infection

Inclusion/Exclusion Criteria

Supplementary Figure 1

Ongoing HIV Replication During ART Reconsidered

Memory NK cells during mousepox infection. Min Fang, Ph.D, Professor Institute of Microbiology, Chinese Academy of Science

Small-Molecule Chemotherapeutic Drugs Reactivate HIV-1 via Non-Canonical Pathways and Modulate CD8 T cell response

T-Pharmacytes for the Targeted Eradication of HIV Reservoirs

Early Antiretroviral Therapy

Rapid perforin upregulation directly ex vivo by CD8 + T cells is a defining characteristic of HIV elite controllers

Will Antigen Depletion Restore HBVspecific

HIV-1 Dual Infection and Neurocognitive Impairment

FOCiS. Lecture outline. The immunological equilibrium: balancing lymphocyte activation and control. Immunological tolerance and immune regulation -- 1

Models of HIV during antiretroviral treatment

MedChem 401~ Retroviridae. Retroviridae

State of the ART: HIV Cure where are we now and. where are we going? Jintanat Ananworanich, MD, PhD MHRP

Antiretroviral Therapy Initiated Within 6 Months of HIV Infection Is Associated With Lower T-Cell Activation and Smaller HIV Reservoir Size

Scott Abrams, Ph.D. Professor of Oncology, x4375 Kuby Immunology SEVENTH EDITION

Inves)gación básica y curación del VIH- 1

ATTACKING THE HIV EPIDEMIC FROM ALL SIDES: OPTIMIZATION OF PCR STRATEGIES TO MEASURE CLONAL EXPANSION AND QUANTITATIVE EVALUATION OF DOLUTEGRAVIR

Supplemental Materials and Methods Plasmids and viruses Quantitative Reverse Transcription PCR Generation of molecular standard for quantitative PCR

Impact of ART in Primary HIV infection on T cell immune exhaustion in Gut- associated lymphoid tissue: Implications for HIV persistence

Fayth K. Yoshimura, Ph.D. September 7, of 7 RETROVIRUSES. 2. HTLV-II causes hairy T-cell leukemia

Isolated Hepatitis B Core Antibody

Immuno-modulatory Strategies for Reduction of HIV Reservoir Cells

Immunologic Failure and Chronic Inflammation. Steven G. Deeks Professor of Medicine University of California, San Francisco

Loss of CD96 Expression as a New Biomarker for T-cell Senescence in HIV-1 Infection

NIH Public Access Author Manuscript J Acquir Immune Defic Syndr. Author manuscript; available in PMC 2013 September 01.

Beyond HAART: Outline. HIV-1 Time Line. Outline. Approaches to HIV Eradication 8/15/2013

Clinical Development of ABX464, drug candidate for HIV Functional Cure. Chief Medical Officer ABIVAX

B cell activation and antibody production. Abul K. Abbas UCSF

Beyond the replication competent HIV reservoir: transcription and translation competent reservoirs

The Role of B Cell Follicles in HIV Replication and Persistence

Imaging B Cell Follicles to Investigate HIV/SIV Persistence. Elizabeth Connick, M.D. University of Arizona May 8, 2017

Impact of antiretroviral therapy on gut immunology and the HIV reservoir in elite controllers

Antigen Presentation and T Lymphocyte Activation. Abul K. Abbas UCSF. FOCiS

Inves&gación básica y curación del VIH-1

T Lymphocyte Activation and Costimulation. FOCiS. Lecture outline

The Generation of Specific Immunity

Professor Mark Bower Chelsea and Westminster Hospital, London

What do we measure when we measure cell associated HIV RNA

cure research HIV & AIDS

Supplementary information. MARCH8 inhibits HIV-1 infection by reducing virion incorporation of envelope glycoproteins

IMMUNOLOGICAL MEMORY. CD4 T Follicular Helper Cells. Memory CD8 T Cell Differentiation

Prevention of infection 2 : immunisation. How infection influences the host : viruses. Peter

New Insights on Mechanisms of Foamy Macrophage (FM) Induction and Persistence

Section Lectures: Immunology/Virology Time: 9:00 am 10:00 am LRC 105 A & B

Transcription:

IAS 25 Towards an HIV Cure symposium Vancouver Distinct HIV Genetic Populations in Effector Memory T Cells after Prolonged Therapy

Questions about long-lived HIV reservoirs Effective ART Memory CD4+ T cell subsets Effect of very prolonged ART (>5 years) on the genetic composition of HIV-DNA? HIV transcripts Full stimulation Relationship between the genetic composition of HIV-DNA and the level of HIV-RNA transcripts? Active viral transcription

Method Overview UCSF: 6 Participants on very prolonged ART >5 years: 4 initiated ART during chronic infection (PT-4) 2 initiated ART during early infection (PT5-6) Leukapheresis Rectal biopsies VGTI: o CD4+ Naïve T cells (T N ) o CD4+ Stem Cell Memory T cells (T SCM ) o CD4+ Central memory T cells (T CM ) o CD4+ Transitional memory T cells (T TM ) o CD4+ Effector memory T cells (T EM ) CD4+ Homing subsets: CXCR5+CCR6- (X5+) CXCR5-CCR6+ (R6+) CXCR5+CCR6+ (X5+R6+) CXCR5-CCR6- (X5-R6-) CD4+ T cells CD8+ T cells CD- T cells CD4-CD8- T cells TILDA (tat/rev induced limiting dilution assay) WMI: DNA sequencing by Single-Proviral Sequencing Gag-pol (p6-rt) sequences

T EM contains clonal HIV-DNA Overall % clonal HIV-DNA T EM was highly enriched with clonally expanded identical HIV-DNA when compared to other cellular subsets PT PT 2 PT PT 4 Overall of 4-66% clonally expanded HIV-DNA in participants treated during chronic infection

2 Mechanisms of Cellular Proliferation Memory CD4+ T cell Antigen specific response Stable pool of CD4+ memory T cells IL-7 IL-2 Large phylogenetic group containing clonally expanded HIV-DNA Small phylogenetic groups containing clonally expanded HIV-DNA

9 9 Cellular proliferation by by antigen-specific homeostatic response.5.2 67. 7 5. 87 89 6 4 59 78 7 5 74 89 82 56 72 6 5 25 8 79 6 29 4 67 7 46 8 PT PT 55 69 4 66 5 6 26 52 7 58 58 44 59 4 4 7 6 49 62 9 96 5 42 7 62 94 2 8 9 2 4 2 PT2 PT4 79 4 49 6 96 25 4 96 4 65 4 95 74 54 5 84 8 8 4 4 62 74 8 4 69 9 86 75 5

Effector memory contain 82% clonal hypermutated HIV-DNA 62. 8 67 6 29 79 72 % Hypermutants in T EM 6 5 56 4 T EM contained 82% clonal hypermutants 25 8 55 7 46 4

Effector memory contain % clonal wild-type HIV-DNA 9 59 74 8 9 4. 5 4 7 4 44 6 69 5 6 7 % of HIV-DNA in T EM were clonal wild-type 54 66 4 7 2 49 25 95 6 94 9 79 4 96 5

Effector memory contain 5% clonal drug resistant HIV-DNA 82.5 87 5% HIV-DNA in T EM clonal HIV-DNA carrying DRMs

6 5 5 7 25 5 4 44 6 Enrichment of hypermutants in T EM (treatment during early infection) 22 29 2.. 6 4 24 7 66 49 2 46 5 2 59 6 9 5 2 6 Hypermutants 45 62 PT5 % Diversity=.7% 52 46 8 6 PT6 % Diversity= 2.5% 49 65 7 9 2 66 Premature stops

Inducible HIV transcripts in CD4+ memory subsets T CM, T TM and T EM subsets derived from all participants produced multiply spliced HIV transcripts upon full stimulation

Conclusions The distribution of HIV- genetic material among memory subsets varied dramatically across the cohort after prolonged ART. Clonal expansions of HIV-DNA can be driven by random antigen-driven cellular proliferation and/or homeostatic response. T EM are marked by clonal expansions with distinctive HIV-DNA genetic populations which reflects cellular proliferation induced by antigen-specific response. Genetic analysis reveals that proliferative bursts can be attenuated by cellular restriction factors and/or by death of cells expressing replication competent virus. The amount of inducible viral transcripts is lower in T EM from an individual with expanded hypermutant populations.

Acknowledgements Palmer lab WMI: Centre for Virus Research/Karolinska Associate Professor S. Palmer K. Barton J-S Eden B. Hiener S. von Stockenstrӧm A. Winckelmann WMI: Centre for Virus Research Professor T. Cunningham A. Harman N. Nasr M. Kim K. Sandgren Rachel, Kirstie, Ani, Naomi, Daisy, Abdullah, Joey AGRF Bhawana Nain and her team VGTIFL/Montreal N.Chomont R.Fromentin Department of Epidemiology and Biostatics UCSF P. Bacchetti Leidos Biomedical Research Inc. Frederick National Laboratory for Cancer Research W. Shao Immunology Laboratory, Vaccine Research Centre, NIH E. Boritz D. Douek Department of Medicine UCSF F. M. Hecht S. G. Deeks M. Somsouk P. Hunt D. Douek E. Sinclair P. Lewis H. Hatano L. Epling M. Kilian T. Ho A. Tan J. Custer L. Loeb R. Hoh L. Poole We acknowledge with gratitude the participants of this study